Adamis Pharmaceuticals (ADMP) Gains Despite Mylan's Generic EpiPen

August 29, 2016 7:57 AM EDT
Get Alerts ADMP Hot Sheet
Trade ADMP Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Adamis Pharmaceuticals (NASDAQ: ADMP) is gaining again despite news that Mylan (NYSE: MYL) announced plans to launch the first generic of its own EpiPen amid scrutiny over its pricing practices.

Adamis Pharmaceuticals offers its own pre-filled epinephrine syringe, which is under review with the FDA. The company said its product would be 40% less than EpiPen.

ADMP is up 3.8% in pre-open trade Monday after gaining 25% on Friday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Momentum Movers, Trader Talk

Related Entities

Pre Market Movers

Add Your Comment